Cargando…

Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota

Resveratrol (RSV) is a potential alternative therapy for non-alcoholic fatty liver disease (NAFLD) that has been evaluated in many clinical trials, but the mechanisms of RSV action have not been fully elucidated. Recent studies suggested that the gut microbiota is an important RSV target; therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Fan, Huang, Rongfeng, Lin, Dan, Wang, Yuying, Yang, Xiaohuang, Huang, Xiaoyun, Zheng, Biyun, Chen, Zhixin, Huang, Yuehong, Wang, Xiaozhong, Chen, Fenglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942199/ https://www.ncbi.nlm.nih.gov/pubmed/33708180 http://dx.doi.org/10.3389/fmicb.2021.611323

Ejemplares similares

Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases
por: Shabangu, Ciniso Sylvester, et al.
Publicado: (2020)

Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease
por: Kato, Ken-ichiro, et al.
Publicado: (2015)

Effect of resveratrol on non-alcoholic fatty liver disease
por: Theodotou, Marios, et al.
Publicado: (2019)

Tert-Butylhydroquinone alleviates insulin resistance and liver steatosis in diabetes
por: Zhu, Tian-tian, et al.
Publicado: (2022)

Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome
por: Chen, Li-Da, et al.
Publicado: (2019)

Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
por: Melton, Phillip E., et al.
Publicado: (2023)

Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
por: Huang, Yan, et al.
Publicado: (2022)

Alleviation Effects of Microbial Metabolites from Resveratrol on Non-Alcoholic Fatty Liver Disease
por: Guo, Jingling, et al.
Publicado: (2022)

Automated assessment of steatosis in murine fatty liver
por: Sethunath, Deepak, et al.
Publicado: (2018)

Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer
por: Fang, Xuefen, et al.
Publicado: (2022)

A Single Strain of Lactobacillus (CGMCC 21661) Exhibits Stable Glucose- and Lipid-Lowering Effects by Regulating Gut Microbiota
por: Wang, Yuying, et al.
Publicado: (2023)

Fagopyrum dibotrys extract alleviates hepatic steatosis and insulin resistance, and alters autophagy and gut microbiota diversity in mouse models of high-fat diet-induced non-alcoholic fatty liver disease
por: Zhang, Dan, et al.
Publicado: (2022)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Alnimer, Lynna, et al.
Publicado: (2023)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Nogami, Asako, et al.
Publicado: (2023)

Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease
por: Dai, Yi-Ning, et al.
Publicado: (2022)

Involvement of 5′AMP-Activated Protein Kinase (AMPK) in the Effects of Resveratrol on Liver Steatosis
por: Trepiana, Jenifer, et al.
Publicado: (2018)

Alternation of plasma fatty acids composition and desaturase activities in children with liver steatosis
por: Hua, Man-Chin, et al.
Publicado: (2017)

Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease
por: Wang, Huan, et al.
Publicado: (2023)

Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease
por: Zhao, Ruifang, et al.
Publicado: (2020)

The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys
por: Singh, Sheo B., et al.
Publicado: (2016)

PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease
por: Aragonès, Gemma, et al.
Publicado: (2016)

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
por: Ferro, Yvelise, et al.
Publicado: (2022)

Non-alcoholic fatty liver and the gut microbiota
por: Bashiardes, Stavros, et al.
Publicado: (2016)

Resveratrol inhibits nonalcoholic fatty liver disease in rats
por: Bujanda, Luis, et al.
Publicado: (2008)

Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
por: Chen, Hui-Ting, et al.
Publicado: (2020)

Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Nier, Anika, et al.
Publicado: (2020)

Liver-specific ceramide reduction alleviates steatosis and insulin resistance in alcohol-fed mice
por: Correnti, Jason, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease
por: Zhu, Cuiling, et al.
Publicado: (2022)

Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease
por: Guo, Wen, et al.
Publicado: (2021)

Effects of S-adenosylmethionine on liver methionine metabolism and steatosis with ethanol-induced liver injury in rats
por: Gong, Zuojiong, et al.
Publicado: (2008)

Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease
por: Jiang, Meng, et al.
Publicado: (2019)

Hepatorenal Index by B‐Mode Ratio Versus Imaging and Fatty Liver Index to Diagnose Steatosis in Alcohol‐Related and Nonalcoholic Fatty Liver Disease
por: Kjaergaard, Maria, et al.
Publicado: (2022)

Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy
por: Wan, Shuqian, et al.
Publicado: (2018)

Correction: The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys
por: Singh, Sheo B., et al.
Publicado: (2017)

Association Between Skeletal Muscle Mass and Severity of Steatosis and Fibrosis in Non-alcoholic Fatty Liver Disease
por: Guo, Wen, et al.
Publicado: (2022)

Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease
por: Wang, Baohong, et al.
Publicado: (2016)

Depletion of Liver Kupffer Cells Prevents the Development of Diet-Induced Hepatic Steatosis and Insulin Resistance
por: Huang, Wan, et al.
Publicado: (2010)

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
por: Ahn, Sang Bong
Publicado: (2023)

High-fructose feeding does not induce steatosis or non-alcoholic fatty liver disease in pigs
por: Schmidt, Nikolaj H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7es422o1e16190ilnim4clrucq